CytoSorbents Corporation Files Amendment No. 1 to Annual Report on Form 10-K: Key Details for Investors

Summary of Filing

CytoSorbents Corporation (“the Company”), a medical device company listed on the Nasdaq Capital Market (Ticker: Not explicitly stated in visible section), has filed its Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment (“10-K/A”) was submitted to the Securities and Exchange Commission (SEC) and is primarily intended to provide the information required by Part III of Form 10-K, which was omitted from the original filing.

Key Points and Potentially Price-Sensitive Information

• Purpose of Amendment: The amendment includes detailed disclosures about directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accounting fees. It does not include or amend financial statements, nor does it modify prior disclosures except as noted in the amendment itself.
• Market Capitalization and Shares Outstanding:
  • As of June 30, 2025, the aggregate market value of CytoSorbents’ common stock held by non-affiliates was approximately \$60.6 million.
  • As of March 20, 2026, there were approximately 62.7 million shares of common stock outstanding.
• Restatement Disclosure: The amendment reflects the correction of an error to previously issued financial statements. However, it clarifies that there are no restatements that required a recovery analysis of incentive-based compensation for executive officers.
• Filer Status: CytoSorbents is classified as a non-accelerated filer and a smaller reporting company. It is not an emerging growth company.
• Corporate Governance Highlights:
  • The Company’s Board consists of a majority of independent directors.
  • Committees include Audit, Compensation, and Nominating & Corporate Governance Committees.
  • Policies and procedures for reviewing and approving related person transactions are in place, overseen by the Audit Committee.
  • The Company maintains a Code of Business Conduct and Ethics and a strict Insider Trading Policy which prohibits hedging/pledging of company securities by officers and directors.
• Executive and Director Compensation:
  • Detailed compensation tables are provided, showing cash, stock, and option awards for 2024 and 2025 for named executive officers and directors.
  • Notably, Dr. Chan (CEO) received \$359,352 in salary and \$266,775 in option awards for 2024, and is entitled to a \$12,000 annual car allowance. The CFO and COO also received substantial compensation packages, with detailed breakdowns of stock-based awards and outstanding options.
  • Directors such as Michael G. Bator and Alan D. Sobel received significant cash and option awards for their service.
• Delinquent Section 16(a) Reporting: All officers and directors complied with SEC ownership reporting requirements, except for a late Form 4 by director Michael G. Bator for one transaction, which was subsequently filed.
• Stockholder Communications and Board Nominee Recommendations: The Company outlines clear procedures for shareholder communications with the Board and for nominating directors.
• Equity Awards:
  • Disclosures include outstanding equity awards, vesting schedules, and grant terms for executive officers.
  • On August 8, 2025, new stock options were granted to Dr. Chan (CEO), Mr. Marini, Mr. Capponi, and Dr. Deliargyris at an exercise price of \$1.00/share, with vesting over three years.
• Other Policies:
  • No retroactive clawback policy in place for compensation based on financial results later subject to restatement.
  • Prohibition of hedging/pledging transactions and derivative securities transactions by insiders.

Shareholder Considerations and Potential Market Impact

• No Financial Statement Changes: The amendment does not introduce new or revised financial results, so immediate price sensitivity from financial performance is limited.
• Governance and Compensation Transparency: The detailed disclosures on board structure, compensation, and related party transaction oversight may reassure investors about governance practices. The late Section 16(a) filing by one director is noted, but appears minor and unlikely to impact share value.
• Equity Award Practices: The new stock option grants, vesting schedules, and lack of a clawback policy for restated results are relevant for evaluating potential dilution and incentive alignment.
• Policy on Material Nonpublic Information: The Company states it does not time equity awards in relation to the release of material nonpublic information, which addresses some investor concerns about the timing of insider compensation.
• Potential Triggers for Future Price Moves: While this amendment itself contains no new operational or financial guidance, the disclosures about outstanding options and their potential dilution, governance practices, and executive compensation structures are key for long-term valuation and may influence investor sentiment.

Conclusion

This 10-K/A filing by CytoSorbents Corporation is primarily administrative, filling in Part III disclosures omitted from the original 10-K. There are no new earnings, revenue, or financial outlook items. The most potentially price-sensitive information relates to executive and director compensation, new stock option grants, and governance/oversight practices. These may influence investor views on the alignment of management with shareholders and the potential for future dilution from outstanding options.

Disclaimer

The information above is a summary of CytoSorbents Corporation’s 10-K/A filing for the fiscal year ended December 31, 2025. It is intended for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should always review the full SEC filings and consult with their financial advisors before making investment decisions.

View Cytosorbents Corp Historical chart here